NAPPA
North America Pharmaceutical Professional Alliance

Connecting global biopharma to partnerships that matter.

NAPPA is a global biopharma alliance connecting companies, investors, scientists, and industry leaders across North America, Europe, Asia-Pacific, and other key innovation hubs to enable high-impact partnerships, licensing opportunities, and cross-border collaboration.

Explore partnerships Become a member
Featured
Partnership

NAPPA and TONACEA join forces ahead of CPIC 2026

A strategic partnership ahead of the China Pharmaceutical Innovation and Competitiveness Conference (CPIC) 2026, formalizing a joint commitment to cross-border execution between U.S. and Chinese biopharma.

Read the full story →
What we do

Execution-focused support across the biopharma lifecycle.

01

BD & Capital

Cross-border partnerships, strategic licensing, M&A, and the creation of new ventures.

02

R&D Enablement

Connecting innovators with preclinical and clinical development expertise, and CRO/CDMO partners.

03

Market Access

Strategic guidance on U.S.–China regulatory pathways and commercialization support.

04

Talent & Network

High-level talent matching and a curated global industry exchange for members.

The NAPPA model

Credibility meets delivery.

Many cross-border partnerships struggle to move beyond introductory conversations. NAPPA is structured to fix that: a non-profit platform that builds trust and ecosystem connections, paired with a commercial arm that takes high-value projects across the finish line.

How it works
Track 1

Non-profit platform

Ecosystem building, advisory access, and seamless resource connection across NAPPA's global network.

Track 2

Commercial arm

Efficient execution of complex, high-value cross-border projects — from BD diligence through deal close.

Advisory framework

Four pillars determine a platform's ceiling.

Scientific capability, industry experience, and capital acumen — they only deliver outcomes when they coexist. NAPPA's advisory board is structured around the four dimensions cross-border execution actually requires.

01

Science

Xumu Zhang
Dean, Medi-X Institute, SUSTech
02

Drug R&D

Dr. Mann Fung
Former CEO, Tavotek Biotherapeutics
03

Industry Translation

Qin Chao Lu
Founding Partner, Danlu Capital
04

Capital

Xin Sylvia He, PhD
Managing Partner, Hyfinity Investments
Meet the full advisory board →
Latest

News & Events

See all news →
Appointment

NAPPA appoints Chen Feng as Shanghai Regional Head

Boren Capital's founder joins NAPPA to deepen the alliance's footprint in China's leading biopharma and capital hub.

Read more →
Appointment

NAPPA welcomes Dr. Hongwen Zhu as Scientific Advisor

A neuroscientist, chief physician, and digital-health builder joins NAPPA's scientific advisory bench.

Read more →
Appointment

NAPPA welcomes Dr. Joy Wang as Strategic Advisor

20+ years of portfolio strategy and Go/No-go decision experience across Novartis, Eli Lilly, Baxter, and Dendreon joins NAPPA's advisory bench.

Read more →
Membership

Join NAPPA.

Become part of an execution-driven global network bridging North American innovation with Asia-Pacific industrial scale and capital.

View membership tiers
Individual
$100/year
  • Member-only events & roundtables
  • Newsletter & deal-flow digest
  • Working group participation
  • Member directory access
Company
$500/year
  • Everything in Individual
  • Logo placement on NAPPA channels
  • Partnership & sourcing introductions
  • Listing in licensing/sourcing channels